CN109069478A - Z-亚丁基苯酞于活化自体免疫***的应用 - Google Patents
Z-亚丁基苯酞于活化自体免疫***的应用 Download PDFInfo
- Publication number
- CN109069478A CN109069478A CN201780028428.9A CN201780028428A CN109069478A CN 109069478 A CN109069478 A CN 109069478A CN 201780028428 A CN201780028428 A CN 201780028428A CN 109069478 A CN109069478 A CN 109069478A
- Authority
- CN
- China
- Prior art keywords
- cell
- injection
- butylidenephthalide
- medicament
- monokaryon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001363 autoimmune Effects 0.000 title claims abstract description 21
- 230000004913 activation Effects 0.000 title claims abstract description 12
- WMBOCUXXNSOQHM-FLIBITNWSA-N (Z)-3-butylidenephthalide Chemical compound C1=CC=C2C(=C/CCC)/OC(=O)C2=C1 WMBOCUXXNSOQHM-FLIBITNWSA-N 0.000 title claims description 55
- WMBOCUXXNSOQHM-UHFFFAOYSA-N n-butylidenephthalide Natural products C1=CC=C2C(=CCCC)OC(=O)C2=C1 WMBOCUXXNSOQHM-UHFFFAOYSA-N 0.000 title claims description 55
- WMBOCUXXNSOQHM-DHZHZOJOSA-N 3-Butylidenephthalide Natural products C1=CC=C2C(=C/CCC)\OC(=O)C2=C1 WMBOCUXXNSOQHM-DHZHZOJOSA-N 0.000 title claims description 54
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 68
- 210000003322 glomus cell Anatomy 0.000 claims abstract description 60
- 201000011510 cancer Diseases 0.000 claims abstract description 54
- 239000003814 drug Substances 0.000 claims abstract description 47
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- UEZOVLHYNZGVIZ-UCOQDCIUSA-N C(/CCC)=C\1/OC(=O)C2=CC=CC=C12.C(/CCC)=C\1/OC(=O)C2=CC=CC=C12 Chemical compound C(/CCC)=C\1/OC(=O)C2=CC=CC=C12.C(/CCC)=C\1/OC(=O)C2=CC=CC=C12 UEZOVLHYNZGVIZ-UCOQDCIUSA-N 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims description 65
- 238000002347 injection Methods 0.000 claims description 31
- 239000007924 injection Substances 0.000 claims description 31
- 238000012360 testing method Methods 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 18
- 102000036639 antigens Human genes 0.000 claims description 18
- 108091007433 antigens Proteins 0.000 claims description 18
- 230000001900 immune effect Effects 0.000 claims description 18
- 230000037396 body weight Effects 0.000 claims description 14
- 239000002552 dosage form Substances 0.000 claims description 14
- 238000002659 cell therapy Methods 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 9
- 210000002865 immune cell Anatomy 0.000 claims description 9
- 238000002513 implantation Methods 0.000 claims description 9
- 238000010253 intravenous injection Methods 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 8
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 7
- 230000001737 promoting effect Effects 0.000 claims description 7
- 210000003491 skin Anatomy 0.000 claims description 6
- 238000010254 subcutaneous injection Methods 0.000 claims description 6
- 239000007929 subcutaneous injection Substances 0.000 claims description 6
- 230000029305 taxis Effects 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 210000004443 dendritic cell Anatomy 0.000 claims description 5
- 210000000987 immune system Anatomy 0.000 claims description 5
- 239000007927 intramuscular injection Substances 0.000 claims description 5
- 238000010255 intramuscular injection Methods 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 210000003979 eosinophil Anatomy 0.000 claims description 4
- 210000003630 histaminocyte Anatomy 0.000 claims description 4
- 239000007928 intraperitoneal injection Substances 0.000 claims description 4
- 238000007913 intrathecal administration Methods 0.000 claims description 4
- 210000002540 macrophage Anatomy 0.000 claims description 4
- 210000000066 myeloid cell Anatomy 0.000 claims description 4
- 210000000822 natural killer cell Anatomy 0.000 claims description 4
- 210000000440 neutrophil Anatomy 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 210000001539 phagocyte Anatomy 0.000 claims description 4
- 210000000130 stem cell Anatomy 0.000 claims description 4
- 230000002594 corticospinal effect Effects 0.000 claims description 3
- 210000003714 granulocyte Anatomy 0.000 claims description 3
- 201000005296 lung carcinoma Diseases 0.000 claims description 3
- 210000002752 melanocyte Anatomy 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- 241000700159 Rattus Species 0.000 description 22
- 230000000694 effects Effects 0.000 description 16
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 15
- 238000000034 method Methods 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 7
- 230000036039 immunity Effects 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 102000008096 B7-H1 Antigen Human genes 0.000 description 3
- 108010074708 B7-H1 Antigen Proteins 0.000 description 3
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 3
- 229940045513 CTLA4 antagonist Drugs 0.000 description 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 3
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 3
- 102100022338 Integrin alpha-M Human genes 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 235000010603 pastilles Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- -1 tackifier Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Natural products O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 1
- 229920000305 Nylon 6,10 Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 108091007744 Programmed cell death receptors Proteins 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 239000003230 hygroscopic agent Substances 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 210000002804 pyramidal tract Anatomy 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
一种使用Z‑亚丁基苯酞(Z‑butylidenephthalide)于制造一药剂的用途，其中该药剂与单核球细胞合并使用于活化自体免疫***及治疗癌症的至少一种。
Description
PCT国内申请，说明书已公开。
Claims (17)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662340246P | 2016-05-23 | 2016-05-23 | |
| US62/340,246 | 2016-05-23 | ||
| PCT/CN2017/084455 WO2017202227A1 (zh) | 2016-05-23 | 2017-05-16 | Z-亚丁基苯酞于活化自体免疫***的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109069478A true CN109069478A (zh) | 2018-12-21 |
| CN109069478B CN109069478B (zh) | 2021-07-06 |
Family
ID=60329303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780028428.9A Active CN109069478B (zh) | 2016-05-23 | 2017-05-16 | Z-亚丁基苯酞于活化自体免疫***的应用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10688128B2 (zh) |
| EP (1) | EP3466422B1 (zh) |
| JP (1) | JP6824287B2 (zh) |
| CN (1) | CN109069478B (zh) |
| ES (1) | ES2850498T3 (zh) |
| TW (1) | TWI640310B (zh) |
| WO (1) | WO2017202227A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114945364A (zh) * | 2020-01-14 | 2022-08-26 | 长弘生物科技股份有限公司 | 用于癌症治疗的组合及其应用 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994026875A1 (en) * | 1993-05-18 | 1994-11-24 | I.D.M. Immuno-Designed Molecules | New macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions |
| CN1503678A (zh) * | 2001-04-26 | 2004-06-09 | 3 | 激活的外周血单核细胞在治疗癌症方面的应用 |
| CN1943606A (zh) * | 2005-10-08 | 2007-04-11 | 财团法人佛教慈济综合医院 | 用于治疗癌症的当归萃取物 |
| EP2343051A3 (en) * | 2010-01-05 | 2012-03-14 | National Dong Hwa University | Anti-cancer formulation |
| US20140065096A1 (en) * | 2012-09-05 | 2014-03-06 | Regen BioPharma, Inc. | Cancer therapy by ex vivo activated autologous immune cells |
| CN105267205A (zh) * | 2014-06-04 | 2016-01-27 | 中国医药大学 | 治疗胰脏癌的医药配方及其应用 |
| WO2016014613A1 (en) * | 2014-07-22 | 2016-01-28 | The Trustees Of The University Of Pennsylvania | Compositions and methods for cancer immunotherapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG121980A1 (en) * | 2004-10-08 | 2006-05-26 | Buddhist Tzu Chi General Hospi | Angelicae sinensis extracts useful for treatment of cancers |
| EP1937250B1 (en) * | 2005-05-24 | 2011-10-19 | DSM IP Assets B.V. | Ligustilide derivatives for the treatment of inflammatory disorders |
| JP2007082422A (ja) | 2005-09-20 | 2007-04-05 | Oncorex Inc | 低酸素条件下において遊走能を有する樹状細胞、およびその利用 |
| TWI331033B (en) * | 2007-04-26 | 2010-10-01 | Yangsen Biotechnology Co Ltd | Composition for inhibiting no and/or prostaglandin e2 synthesis and uses thereof |
| TWI386203B (zh) * | 2011-01-07 | 2013-02-21 | Univ China Medical | 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用 |
-
2017
- 2017-05-16 WO PCT/CN2017/084455 patent/WO2017202227A1/zh active Search and Examination
- 2017-05-16 EP EP17802073.1A patent/EP3466422B1/en active Active
- 2017-05-16 TW TW106116111A patent/TWI640310B/zh active
- 2017-05-16 ES ES17802073T patent/ES2850498T3/es active Active
- 2017-05-16 CN CN201780028428.9A patent/CN109069478B/zh active Active
- 2017-05-16 US US15/596,858 patent/US10688128B2/en active Active
- 2017-05-16 JP JP2018556981A patent/JP6824287B2/ja active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994026875A1 (en) * | 1993-05-18 | 1994-11-24 | I.D.M. Immuno-Designed Molecules | New macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions |
| CN1503678A (zh) * | 2001-04-26 | 2004-06-09 | 3 | 激活的外周血单核细胞在治疗癌症方面的应用 |
| CN1943606A (zh) * | 2005-10-08 | 2007-04-11 | 财团法人佛教慈济综合医院 | 用于治疗癌症的当归萃取物 |
| EP2343051A3 (en) * | 2010-01-05 | 2012-03-14 | National Dong Hwa University | Anti-cancer formulation |
| US20140065096A1 (en) * | 2012-09-05 | 2014-03-06 | Regen BioPharma, Inc. | Cancer therapy by ex vivo activated autologous immune cells |
| CN105267205A (zh) * | 2014-06-04 | 2016-01-27 | 中国医药大学 | 治疗胰脏癌的医药配方及其应用 |
| WO2016014613A1 (en) * | 2014-07-22 | 2016-01-28 | The Trustees Of The University Of Pennsylvania | Compositions and methods for cancer immunotherapy |
Non-Patent Citations (2)
| Title |
|---|
| 傅冰洁等: "肿瘤的细胞免疫治疗", 《中国处方药》 * |
| 张迪: "当归的免疫药理作用研究", 《黑龙江科技信息》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3466422A1 (en) | 2019-04-10 |
| JP6824287B2 (ja) | 2021-02-03 |
| TWI640310B (zh) | 2018-11-11 |
| WO2017202227A1 (zh) | 2017-11-30 |
| CN109069478B (zh) | 2021-07-06 |
| US20170333478A1 (en) | 2017-11-23 |
| TW201740938A (zh) | 2017-12-01 |
| EP3466422A4 (en) | 2020-03-11 |
| ES2850498T3 (es) | 2021-08-30 |
| JP2019519482A (ja) | 2019-07-11 |
| US10688128B2 (en) | 2020-06-23 |
| EP3466422B1 (en) | 2020-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7794713B2 (en) | Compositions and methods for the treatment and prevention of hyperproliferative diseases | |
| JP6568052B2 (ja) | 心不全を治療するためのニューレグリンの徐放 | |
| Chiu et al. | Molecular machinery and pathophysiology of mitochondrial dynamics | |
| Wang et al. | Remote ischemic postconditioning protects against myocardial ischemia‐reperfusion injury by inhibition of the RAGE‐HMGB1 pathway | |
| US20130323283A1 (en) | Compositions and methods for treating foxp3+ treg related diseases | |
| George et al. | A polymerized bovine hemoglobin oxygen carrier preserves regional myocardial function and reduces infarct size after acute myocardial ischemia | |
| WO2016034081A1 (en) | Methods and compositions for treating c-met associated cancers | |
| CN105560612B (zh) | 一种沉香提取物、包含其的药物组合物及其用途 | |
| Mitchell et al. | A phase 1 trial of TPI 287 as a single agent and in combination with temozolomide in patients with refractory or recurrent neuroblastoma or medulloblastoma | |
| US10517913B2 (en) | Composition for prevention, alleviation, or treatment of peripheral neuropathy comprising Lithospermi Radix extract as an effective component | |
| CN109069478A (zh) | Z-亚丁基苯酞于活化自体免疫***的应用 | |
| US20060210543A1 (en) | Method of treating infarcted myocardium | |
| EP3962365A1 (en) | Prophylactic and therapeutic use of mitochondria and combined mitochondrial agents | |
| Cao et al. | Inhibition of experimental allergic encephalomyelitis in the Lewis rat by paclitaxel | |
| Paschkis et al. | Adrenal cortical hormone levels in adrenal vein—and peripheral blood | |
| US20180008688A1 (en) | Method and compositions for enhancing immunotherapeutic treatment of a cancer | |
| JP2017109987A (ja) | ＥｒｂＢ４＋炎症性マクロファージによって媒介される疾患の治療方法 | |
| KR101121954B1 (ko) | 1,2,3-Ｂｅｎｚｅｎｔｒｉｃａｒｂｏｘｙｌｉｃ ａｃｉｄ를 유효성분으로 포함하는 당뇨병 예방 또는 치료용 조성물 | |
| US20190160106A1 (en) | Compositions and methods for treating cardiac injury | |
| US20240139240A1 (en) | Small extracellular vesicles for attenuating post-operative pain | |
| Dong et al. | Apigenin inhibits pressure overloadinduced cardiac hypertrophy | |
| CN104940193B (zh) | 一种含辛伐他汀的降血脂血糖药物组合物及其应用 | |
| Linnestad et al. | The effect of alpha-and beta-adrenergic agonists and blockers on postprandial pancreatic polypeptide release in dogs | |
| KR20220097312A (ko) | 닌테다닙을 포함하는 암 치료 효과 증진용 조성물 및 이의 용도 | |
| Chechet et al. | Plasma kinetics of intravenously administered lactosein-saline in healthy and Trypanosoma congolense infected rams |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |